Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Cognitive tests and assessment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objectives The efficacy, safety and disease-modification of tramiprosate (homotaurine)were investigated in a recently completed large-scale Phase III clinical study in patients with mild to moderate Alzheimer's disease (AD), the Alphase study. Disease-modification was assessed using longitudinal volumetric MRI (vMRI) measurements of the hippocampus in a subgroup of patients. The present study describes the vMRI, cognitive and clinical results obtained in this subgroup.

What this study adds

Evidence grade: High

This is a follow-up (cohort) study of 109 participants. This was a subgroup analysis of a large double-blind, randomized, placebo-controlled trial testing tramiprosate in mild-to-moderate Alzheimer's disease, using hippocampal MRI measurements to assess disease modification. The provided text does not report the results, so it is unknown whether tramiprosate affected brain volume, cognition, or clinical outcomes.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gauthier, S., Aisen, P. S., Ferris, S. H., Saumier, D., Duong, A., Haine, D., et al. (2009). Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. The journal of nutrition, health & aging. https://doi.org/10.1007/s12603-009-0106-x

Vancouver

Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. The journal of nutrition, health & aging. 2009. doi:10.1007/s12603-009-0106-x. PMID: 19536424.

BibTeX

@article{gauthier2009-19536424,
  author  = {Gauthier, S. and Aisen, P. S. and Ferris, S. H. and Saumier, D. and Duong, A. and Haine, D. and Garceau, D. and Suhy, J. and others},
  title   = {{Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study}},
  journal = {The journal of nutrition, health \& aging},
  year    = {2009},
  doi     = {10.1007/s12603-009-0106-x},
  pmid    = {19536424},
  url     = {https://doi.org/10.1007/s12603-009-0106-x}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This was a subgroup analysis of a large double-blind, randomized, placebo-controlled trial testing tramiprosate in mild-to-moderate Alzheimer's disease, using hippocampal MRI measurements to assess disease modification. The provided text does not report the results, so it is unknown whether tramiprosate affected brain volume, cognition, or clinical outcomes.

Study details

How this study scored 68/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 5 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 68 of 100.68 of 100 points earned32 not earned

Published in a peer-reviewed journal, and it is a large phase 3 trial. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The journal of nutrition, health & aging)
Journal's citation record 1 / 4 The journal of nutrition health & aging: journal h-index 122 (OpenAlex, 2026-10-29)
Study design 11 / 12 A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2009 — within 20 year(s) of the newest study here
Sample size 2 / 4 109 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 5 / 7 Cited 135 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.1 citations a year over 19 year(s) since 2009
Impact for its field and year 4 / 6 Cited 9.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 7 other studies in this library
Still being cited 1 / 4 Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author John S. Sampalis: h-index 53 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California San Diego: institution h-index 1,852 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 10 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 19536424)
Free to read 2 / 2 Free to read
Total 68 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

7 studies in the alzhub library list this one in their references. Showing the 6 highest-scoring.

Related studies in Cognitive tests and assessment from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →